Altered Myeloid Development and Acute Leukemia in Transgenic Mice Expressing PML-RARα Under Control of Cathepsin G Regulatory Sequences
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Acute promyelocytic leukemia (APML) is characterized by abnormal myeloid development, resulting an accumulation of leukemic promyelocytes that are often highly sensitive to retinoic acid. A balanced t(15; 17) (q22; q21) reciprocal chromosomal translocation is found in approximately 90% of APML patients; this translocation fuses the PML gene on chromosome 15 to the retinoic acid receptor α (RARα) gene on chromosome 17, creating two novel fusion genes, PML-RARα and RARα-PML. The PML-RARα fusion gene product, which is expressed in virtually all patients with t(15; 17), is thought to play a direct role in the pathogenesis of APML. To determine whether PML-RARα is sufficient to cause APML in an animal model, we used the promyelocyte-specific targeting sequences of the human cathepsin G (hCG) gene to direct the expression of a PML-RARα cDNA to the early myeloid cells of transgenic mice. Mice expressing the hCG–PML-RARα transgene were found to have altered myeloid development that was characterized by increased percentages of immature and mature myeloid cells in the peripheral blood, bone marrow, and spleen. In addition, approximately 30% of transgene-expressing mice eventually developed acute myeloid leukemia after a long latent period. The splenic promyelocytes of mice with both the nonleukemic and leukemic phenotypes responded to all-trans retinoic acid (ATRA) treatment, which caused apoptosis of myeloid precursors. Although low-level expression of the hCG–PML-RARα transgene is not sufficient to directly cause acute myeloid leukemia in mice, its expression alters myeloid development, resulting in an accumulation of myeloid precursors that may be susceptible to cooperative transforming events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Kakizuka, A., Miller, W. H., Umesono, K., Warrell, R. P., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., & Evans, R. M. (1991) · Cell · doi:10.1016/0092-8674(91)90112-c · Cited by 1,427
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355
de Thé, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., & Dejean, A. (1991) · Cell · doi:10.1016/0092-8674(91)90113-d · Cited by 1,343
Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242002 · Cited by 1,251
Castaigne, S., Chomienne, C., Daniel, M., Ballerini, P., Berger, R., Fenaux, P., & Degos, L. (1990) · Blood · doi:10.1182/blood.v76.9.1704.1704 · Cited by 1,184
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
Dyck, J. A., Maul, G. G., Miller, W. H., Chen, J. D., Kakizuka, A., & Evans, R. M. (1994) · Cell · doi:10.1016/0092-8674(94)90340-9 · Cited by 785
Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A., & Dejean, A. (1994) · Cell · doi:10.1016/0092-8674(94)90341-7 · Cited by 652
Cited by
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Self-citationMelnick, A., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,028
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Transcription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735
He, L.-Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/ng0298-126 · Cited by 557
G ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
de Thé, H., & Chen, Z. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2943 · Cited by 488
Kelly, L. M., Liu, Q., Kutok, J. L., Williams, I. R., Boulton, C. L., & Gilliland, D. G. (2002) · Blood · doi:10.1182/blood.v99.1.310 · Cited by 487
PML protein isoforms and the RBCC/TRIM motif
Jensen, K., Shiels, C., & Freemont, P. S. (2001) · Oncogene · doi:10.1038/sj.onc.1204765 · Cited by 467
A PMLRAR α transgene initiates murine acute promyelocytic leukemia
Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P. G., Atwater, S., & Bishop, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2551 · Cited by 434
Self-citationYuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C. J., Burel, S. A., Lagasse, E., Weissman, I. L., Akashi, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171321298 · Cited by 431
Sequestration and Inhibition of Daxx-Mediated Transcriptional Repression by PML
Li, H., Leo, C., Zhu, J., Wu, X., O'Neil, J., Park, E.-J., & Chen, J. D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1784-1796.2000 · Cited by 364
Hong, S.-H., David, G., Wong, C.-W., Dejean, A., & Privalsky, M. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9028 · Cited by 340
Sternsdorf, T., Jensen, K., & Will, H. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.7.1621 · Cited by 331
PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model
Kelly, L. M., Kutok, J. L., Williams, I. R., Boulton, C. L., Amaral, S. M., Curley, D. P., Ley, T. J., & Gilliland, D. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122233699 · Cited by 322
Self-citationRetinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Müller-Tidow, C., Steffen, B., Cauvet, T., Tickenbrock, L., Ji, P., Diederichs, S., Sargin, B., Köhler, G., Stelljes, M., Puccetti, E., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2890-2904.2004 · Cited by 303
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Malaney, P., Nicosia, S. V., & Davé, V. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.010 · Cited by 289
Oligomerization of RAR and AML1 Transcription Factors as a Novel Mechanism of Oncogenic Activation
Minucci, S., Maccarana, M., Cioce, M., De Luca, P., Gelmetti, V., Segalla, S., Di Croce, L., Giavara, S., Matteucci, C., Gobbi, A., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80321-4 · Cited by 285
Self-citationThe Molecular Basis of Leukemia
Gilliland, D. G., Jordan, C. T., & Felix, C. A. (2004) · Hematology · doi:10.1182/asheducation-2004.1.80 · Cited by 273
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20476 · Cited by 270
Retinoic acid receptors and cancers
Soprano, D. R., Qin, P., & Soprano, K. J. (2004) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.24.012003.132407 · Cited by 270
Retinoids in chemoprevention and differentiation therapy
Hansen, L. A., Sigman, C. C., Andreola, F., Ross, S. A., Kelloff, G. J., & Luca, L. M. D. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.271 · Cited by 270
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
Rhoades, K. L., Hetherington, C. J., Harakawa, N., Yergeau, D. A., Zhou, L., Liu, L.-Q., Little, M.-T., Tenen, D. G., & Zhang, D.-E. (2000) · Blood · doi:10.1182/blood.v96.6.2108 · Cited by 257
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H., & Nerlov, C. (2002) · Blood · doi:10.1182/blood.v99.6.1909 · Cited by 246
Concepts of human leukemic development
Warner, J. K., Wang, J. C. Y., Hope, K. J., Jin, L., & Dick, J. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207933 · Cited by 225
“Transgenic mice expressing PMLRARa display abnormalities in myeloid differentiation, but only develop leukemia after long latency and with limited penetrance (Brown et al., 1997; Grisolano et al., 1997; He et al., 1997).”
BackgroundA murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
Dash, A. B., Williams, I. R., Kutok, J. L., Tomasson, M. H., Anastasiadou, E., Lindahl, K., Li, S., Van Etten, R. A., Borrow, J., Housman, D., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102583199 · Cited by 209
Gilliland, D. G., & Tallman, M. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00081-8 · Cited by 169
The Promyelocytic Leukemia Gene Product (PML) Forms Stable Complexes with the Retinoblastoma Protein
Alcalay, M., Tomassoni, L., Colombo, E., Stoldt, S., Grignani, F., Fagioli, M., Szekely, L., Helin, K., & Pelicci, P. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.1084 · Cited by 161
Self-citationSantilli, G., Almarza, E., Brendel, C., Choi, U., Beilin, C., Blundell, M. P., Haria, S., Parsley, K. L., Kinnon, C., Malech, H. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.226 · Cited by 144
Guibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126
Rosmarin, A. G., Yang, Z., & Resendes, K. K. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.08.015 · Cited by 121
Porse, B. T., Bryder, D., Theilgaard-Mönch, K., Hasemann, M. S., Anderson, K., Damgaard, I., Jacobsen, S. E. W., & Nerlov, C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050067 · Cited by 117
Walter, M. J., Park, J. S., Ries, R. E., Lau, S. K. M., McLellan, M., Jaeger, S., Wilson, R. K., Mardis, E. R., & Ley, T. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504247102 · Cited by 83
Self-citationMolecular pathogenesis of acute promyelocytic leukaemia and APL variants
Sirulnik, A., Melnick, A., Zelent, A., & Licht, J. D. (2003) · Best Practice & Research Clinical Haematology · doi:10.1016/s1521-6926(03)00062-8 · Cited by 54
(2001) · PubMed
Metadata
- Authors
- Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G., & Ley, T. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-01-15
- Volume
- 89
- Issue
- 2
- Pages
- 376-387
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1579062391
- Cited by
- 352
- References
- 43
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.